Sign up
RMTI

Rockwell Medical Inc (NASDAQ: RMTI)

Healthcare · Drug Manufacturers - Specialty & Generic

——

Quote unavailable · Price data is temporarily unavailable.

Set alert

The Quantellect read. The borrow fee is 0.77%. One active firm covers the stock as of Nov 19, 2026; one active firm with a target averages $20.00 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuationLower multiples than peers

P/S 0.4× vs peer median 2.0×

Momentum—

—

Trend—

—

Short interest—

—

RMTI price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range—
Volume—
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

RMTI · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18
Squeeze14Idle—
How the scores work →

How RMTI compares with its industry

Against 83 other US-listed Drug Manufacturers - Specialty & Generic stocks

Dot = rank among peers, low to high · tick = peer median · colour marks the top and bottom 10%

Points of caution

  1. Trailing-year gross margin was 17.7%, with only 12% of 73 peers reporting a lower value.Peer median 57.7% · As of Nov 17, 2026

Valuation

Lower multiples than peers

  • Price/sales0.41×1.99×

    Higher than 18% of 78 peers

  • Forward P/E19.53×14.31×

    Higher than 65% of 63 peers

  • Price/book0.81×1.92×

    Higher than 28% of 82 peers

Profitability

Profitability metrics are lower than most peers.

  • Gross margin17.7%57.7%

    Higher than 12% of 73 peers

  • Operating margin−6.0%2.1%

    Higher than 30% of 74 peers

  • Net margin−7.3%0.0%

    Higher than 37% of 82 peers

  • Return on equity−15.5%−9.3%

    Higher than 47% of 79 peers

Growth

Growth metrics are higher than most peers.

  • Quarterly sales growth, year over year10.6%4.8%

    Higher than 63% of 83 peers

  • 5-year sales growth rate—7.6%

    Not ranked: only 41 of 83 peers report it

Balance sheet

Balance sheet metrics are lower than most peers.

  • Current ratio2.472.73

    Higher than 47% of 64 peers

  • Debt/equity (total borrowings)0.270.47

    Not ranked: only 31 of 83 peers report it

Momentum

Returns are lower than most peers.

  • 1-year return−29.5%−12.1%

    Higher than 41% of 74 peers

  • 6-month return−25.6%−2.2%

    Higher than 38% of 77 peers

  • 3-month return−20.2%−7.8%

    Higher than 42% of 78 peers

Compared with 83 other US-listed Drug Manufacturers - Specialty & Generic stocks · fundamentals as of Nov 1, 2026 · prices as of Nov 16, 2026

Upcoming events

— · Upcoming events not available

Analyst consensus

Insufficient coverage

0Strong Buy
1Buy
0Neutral
0Sell
0Strong Sell

Based on 1 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$20.00
Average$20.00
High$20.00

As of Nov 19, 2026 across 1 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q1 2026−$0.03−$0.04—
Annual 2025—−$0.15—
Q3 2025—−$0.05—
Q2 2025—−$0.05—
Q1 2025—−$0.04—
Annual 2024$0.02−$0.03—
Q3 2024$0.10$0.04—
Q2 2024−$0.35$0.01—

Smart-money activity

In the last 60 days: 1 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider sellStrobeck MarkSell$8.4KForm 4
Insider sellHunter HeatherSell$2.4KForm 4
Insider sellNeri JesseSell$740Form 4
Insider sellCOOPER JOHN GSell$4.4KForm 4
Insider sellHunter HeatherSell$3.4KForm 4
Insider sellChole TimothySell$3.4KForm 4
Insider sellNeri JesseSell$1.1KForm 4
Insider sellStrobeck MarkSell$8.2KForm 4
Insider sellChole TimothySell$2.4KForm 4
Insider sellStrobeck MarkSell$5.7KForm 4
All smart-money activity →

News and press releases

All RMTI news →

Company profile

Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as

CEO
Dr. Mark Strobeck Ph.D.
Headquarters
Wixom, MI, United States
Employees
157
IPO date
Jan 27, 1998
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.